GE vs PFE: Which Is the Better Buy?
Side-by-side comparison of GE Aerospace and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
GE Aerospace · Industrials
$312.90
+3.4% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GE |
PFE |
| Current Price |
$312.90 |
$27.64 |
| Fair Value Estimate |
$323.41 |
$30.94 |
| Upside to Fair Value |
+3.4%
|
+12.0%
|
| Market Cap |
$324.6B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
27.4x
|
17.4x
|
| Price / Sales |
6.4x
|
2.5x
|
| Price / FCF |
38.7x
|
14.3x
|
| Revenue Growth YoY |
+21.1%
|
+2.6%
|
| Gross Margin |
35.4%
|
71.3%
|
| Operating Margin |
20.8%
|
25.1%
|
| Return on Equity |
49.0%
|
4.9%
|
| Dividend Yield |
0.53% |
6.22% |
| FCF Yield |
2.58%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
GE Aerospace is a high-quality commercial and military propulsion company whose approximately 50,000 commercial-engine and 30,000 military-engine installed base, long-term service agreements, proprietary repair capabilities and certification barriers support recurring aftermarket economics. The business is executing strongly: revenue grew 21.1% year over year in the most recent quarter, while Q2 …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
GE |
PFE |
| Zone Low |
$242.56 |
$23.21 |
| Zone High |
$274.90 |
$26.30 |
| In Buy Zone? |
No
|
No
|